2024-511222-30-00招募中2 期
A Phase 2a, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Dosing of Exidavnemab in Patients with Mild to Moderate Parkinson’s Disease on Stable Symptomatic Parkinson’s Disease Medication and in Patients with Multiple System Atrophy
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- BioArctic AB
- 入组人数
- 36
- 试验地点
- 7
- 主要终点
- To determine the occurrence of AEs and SAEs after 4 treatment cycles by assessing the frequency, severity, causality, and nature of AEs and SAEs; also changes in ECG, vital signs (arterial blood pressure, heart rate, and temperature), and laboratory tests (hematology, serum chemistry, and urine) will be assessed for tolerability. The severity of the AEs and SAEs will be determined by CTCAE v5.0.
研究概览
简要总结
To assess the safety and tolerability of exidavnemab after multiple dosing versus placebo
研究设计
- 分配方式
- Randomized
- 主要目的
- Cohort 2b
- 盲法
- Double (Subject, Investigator, Monitor)
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- •Inclusion Criteria for Cohorts 1 and 2a (Parkinson’s Disease):
- •Male and female participants 40 to 85 years of age.
- •Participants must have cognition inconsistent with dementia as confirmed by a score of more than or equal to 22 on the MoCA.
- •Stable and optimized symptomatic PD medication, defined as the same list of medications for at least 3 months prior to the Screening Visit with no change in the dose for at least 1 month prior to the Baseline Visit, and no planned changes in dose-regimen during trial participation.
- •Prior (any time; i.e., no time limit) or current DaT-SPECT or DaT-PET consistent with dopamine transporter deficit, as per the Movement Disorder Society Criteria for PD. For participants who have not undergone DaT-SPECT or DaT-PET prior to Screening, or who have previously undergone DaT-SPECT or DaT-PET scan(s) but without results consistent with dopamine transporter deficit, DaT-SPECT or DaT-PET should be performed and read locally as part of the Screening procedures.
- •Positive smell test showing hyposmia, as defined by UPSIT scores of around or below the 15% percentile for their relevant sex and age group.
- •Ability to use tablet device to measure cognitive function, as per Investigator judgment.
- •Inclusion Criteria for Cohort 2b (Multiple System Atrophy): Male and female participants 40 to 85 years of age.
- •Body weight more than or equal to 50 kg and less than or equal to 120 kg.
- •Have clinically established or clinically probable MSA (either MSA-P or MSA-C), as per the Movement Disorder Society criteria for the diagnosis of MSA
- •Classified as Stage 1 to 3 on the modified Hoehn and Yahr scale for the staging of MSA severity.
- •Participants must have cognition inconsistent with dementia as confirmed by a score of more than or equal to 22 on the MoCA.
- •Negative urine or serum pregnancy test at the Screening Visit and Baseline for premenopausal women, and for women who have experienced menopause onset less than 12 months prior to the first planned dose of trial medication.
- •Negative urine or serum pregnancy test at the Screening Visit and Baseline for premenopausal women, and for women who have experienced menopause onset less than 12 months prior to the first planned dose of trial medication.
- •Males and POCBP must agree to practice an effective means of birth control during their participation in the trial and until 3 months after their last dose of the trial medication.
- •Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and trial procedures.
- •The participant is capable of providing informed consent and has signed and dated the ICF before any trial-specific procedures are performed.
- •In the opinion of the Investigator, the participant has an expected survival of at least 6 months beyond the end of their participation in the trial.
- •Males and persons of childbearing potential (POCBP) must agree to practice an effective means of birth control during their participation in the trial and until 3 months after their last dose of the trial medication.
- •Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and trial procedures.
- •Participants must understand their daily medication regimen and must agree that they will not change their daily medication doses during the trial.
- •The participant is capable of providing informed consent and has signed and dated the ICF before any trial specific procedures are performed.
- •Body weight more than or equal to 50 kg and less than or equal to 120 kg.
- •Have idiopathic PD (i.e., not induced by drugs or other diseases) as defined by bradykinesia combined with at least 1 of resting tremor and rigidity, as per the Movement Disorder Society Criteria for PD
- •Classified as Stage 1 to 2.5 on the modified Hoehn and Yahr scale for the staging of PD severity.
排除标准
- •Exclusion Criteria for Cohorts 1 and 2a (Parkinson’s Disease):
- •Known hypersensitivity to trial medication, the infusion solution, or excipients.
- •Severe visual or hearing impairment that, in the Investigator’s opinion, would prevent the participant from accurately completing cognitive testing assessments.
- •Participation in any other clinical trial, being treated with an investigational product less than or equal to 4 weeks prior to the Screening Visit, and less than or equal to 8 weeks if treated with mAbs prior to the Screening Visit.
- •More than 5 years of symptomatic treatment for PD.
- •Any concurrent illness or condition, including but not limited to mental illness, substance abuse, metabolic dysfunction, immunological disease, physical or neurological examination finding or clinical laboratory finding which, in the opinion of the Investigator, would make the participant unable to cooperate or participate in the trial or would represent a potential safety concern. Note: An active or recent (within 3 days) respiratory infection will not disqualify a participant from enrolling in the trial; however, all symptoms should be resolved for at least 5 days prior to the Screening Visit. The Screening Period may be extended for up to 2 weeks to accommodate this recovery.
- •Current significant compulsive behaviors or impaired impulse control in response to a dopaminergic Parkinson’s Disease medication. Any major psychiatric diagnosis, including schizophrenia, bipolar disorder, and current major depressive disorder as per the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V).
- •Renal impairment as defined by a calculated creatinine clearance (CLcr) of less than or equal to 60 mL/min.
- •Positive serology test (hepatitis B virus surface antigen, hepatitis C virus antibody, human immunodeficiency virus 1 and 2 antibodies).
- •Participant has cancer with the exception of the following: basal cell carcinoma or successfully treated squamous cell carcinoma of the skin; cervical carcinoma in situ; prostatic carcinoma in situ; or other malignancies curatively treated and with no evidence of disease recurrence for at least 3 years.
- •Drug or alcohol abuse in the past 1 year (criteria for alcohol abuse as per the DSM-V).
- •Positive urine screen for drugs of abuse that include opiates, cannabis, cocaine, amphetamines, or barbiturates.
- •Abnormal ECG that is or may be clinically significant in the Investigator’s opinion and after consultation with the Medical Monitor, including left bundle branch block, atrial fibrillation, QTcF interval (Fredericia’s correction factor) more than 450 milliseconds (msec) for males and more than 470 milliseconds (msec) for females at the Screening Visit or Baseline.
- •Suicide attempt within 1 year prior to the Screening Visit, or severe suicidal ideation within 6 months prior to the Screening Visit (i.e., the participant answers “Yes” to Questions 4 or 5 in the Baseline-Screening Columbia-Suicide Severity Rating Scale [C-SSRS]), or participant is at significant risk of suicidal behavior in the opinion of the Investigator.
- •Any condition that, in the Investigator’s opinion, would make the participant unable to comply with trial procedures or make them unsuitable for participation in the trial.
- •Participation in any prior exidavnemab study, regardless of treatment group assignment.
- •History of neurosurgical intervention for PD including implantation of brain stimulation.
- •Blood or plasma donation within 3 months prior to Screening.
- •Diagnosis of PD dementia or another dementia.
- •Any psychiatric diagnosis or symptoms (e.g., hallucinations, major depression, or delusions) that could interfere with trial procedures.
- •Freezing episodes occurring on a weekly basis or more frequently.
- •Motor fluctuations occurring on a weekly basis or more frequently.
- •Levodopa-induced troublesome dyskinesia of a severity that would significantly interfere with the participant’s ability to participate or perform trial procedures as determined by the Movement Disorder Society-Sponsored Revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Subscale IV.
- •Systolic blood pressure (SBP) of more than 160 mmHg or diastolic blood pressure (DBP) of more than 95 mmHg on 3 separate determinations 5 minutes apart, taken at same arm, after the participant feels comfortable and relaxed at the research facility to minimize or avoid “white coat hypertension.”
- •History of significant cardiovascular disease or arrhythmia within 6 months of Screening.
- •Females who intend to breastfeed during the trial and for up to 3 months after the last dose of trial medication.
- •Exclusion Criteria for Cohort 2b (Multiple System Atrophy):
- •Known hypersensitivity to the trial medication, the infusion solution, or excipients.
- •Any psychiatric diagnosis or symptoms (e.g., hallucinations, major depression, or delusions) that could interfere with trial procedures.
- •History of significant cardiovascular disease or arrhythmia within 6 months of Screening.
- •Abnormal ECG that is or may be clinically significant in the Investigator’s opinion and after consultation with the Medical Monitor, including left bundle branch block, atrial fibrillation, QTcF more than 450 msec for males and more than 470 msec for females at the Screening Visit or Baseline.
- •History of transient ischemic attacks, stroke, or seizures within 12 months of Screening.
- •Abnormal liver function tests: GGT, TBil, ALP, ALT, and AST higher than the ULN and regarded as potentially clinically significant by the Investigator. Note: Gilbert’s syndrome is not exclusionary.
- •Poorly controlled diabetes as defined by hemoglobin A1C of more than 8%.
- •Contraindication, condition, or concomitant medication incompatible with lumbar puncture (e.g., lumbar scoliosis, coagulopathy, and infected skin at needle puncture site), 1.5T or 3T MRI (e.g., aneurysm clip, metal fragments [e.g., in-skull and cardiac devices other than those approved as safe for use in MRI scanners], and internal electrical devices such as a cochlear implant, spinal cord stimulator, or cardiac pacemaker/defibrillator).
- •A history of clinically significant orthostatic hypotension or syncope, or orthostatic hypotension at the Screening Visit or Baseline, defined as a SBP decrease more than or equal to 20 mmHg or DBP decrease more than or equal to 10 mmHg when standing up from sitting or lying down, and/or use of medications to treat orthostatic hypotension (e.g., droxidopa, fludrocortisone) and/or presence of severe dysautonomia.
- •Taking prohibited medications; use of immunomodulatory or immunosuppressive therapy (immunoglobulins, systemic mAbs [or derivatives of mAbs], systemic immunosuppressant drugs [including azathioprine, methotrexate, mycophenolate mofetil], or plasmapheresis); use of dopaminergic antagonist therapy. Note: Use of low-dose cortisone derivatives for orthostatic hypotension is permitted, as are topical corticosteroids. Use of anticoagulants (including coumarins, heparin, and derivatives) and antiplatelet drugs is permitted but must be temporarily suspended prior to and after execution of lumbar puncture, according to the prescribing information.
- •Participation in any other clinical trial, being treated with an investigational product less than or equal to 4 weeks prior to the Screening Visit, and less than or equal to 8 weeks if treated with mAbs prior to the Screening Visit.
- •Any concurrent illness or condition, including but not limited to mental illness, substance abuse, metabolic dysfunction, immunological disease, physical or neurological examination finding, or clinical laboratory finding which, in the opinion of the Investigator, would make the participant unable to cooperate or participate in the trial or would represent a potential safety concern. Note: An active or recent (within 3 days) respiratory infection will not disqualify a participant from enrolling in the trial; however, all symptoms should be resolved at least 5 days prior to the Screening Visit. The Screening Period may be extended for up to 2 weeks to accommodate this recovery.
- •Any major psychiatric diagnosis, including schizophrenia, bipolar disorder, and current major depressive disorder as per DSM-V.
- •Renal impairment as defined by a calculated CLcr of less than or equal to 60 mL/min.
- •Positive serology test (hepatitis B virus surface antigen, hepatitis C virus antibody, human immunodeficiency virus 1 and 2 antibodies).
- •Participant has cancer with the exception of the following: basal cell carcinoma or successfully treated squamous cell carcinoma of the skin; cervical carcinoma in situ; prostatic carcinoma in situ; or other malignancies curatively treated and with no evidence of disease recurrence for at least 3 years.
- •Drug or alcohol abuse in the past 1 year (criteria for alcohol abuse as per the DSM-V).
- •Positive urine screen for drugs of abuse that include opiates, cannabis, cocaine, amphetamines, or barbiturates.
- •Suicide attempt within 1 year prior to the Screening Visit, or severe suicidal ideation within 6 months prior to the Screening Visit (i.e., the participant answers “Yes” to Questions 4 or 5 in the Baseline-Screening C-SSRS), or the participant is at significant risk of suicidal behavior in the opinion of the Investigator.
- •History of transient ischemic attacks, stroke, or seizures within 12 months of Screening.
- •Any condition that, in the Investigator’s opinion, would make the participant unable to comply with trial procedures or make them unsuitable for participation in the trial.
- •Participation in any prior exidavnemab study, regardless of treatment group assignment.
- •Blood or plasma donation within 3 months prior to Screening.
- 另有 7 项未显示
结局指标
主要结局
To determine the occurrence of AEs and SAEs after 4 treatment cycles by assessing the frequency, severity, causality, and nature of AEs and SAEs; also changes in ECG, vital signs (arterial blood pressure, heart rate, and temperature), and laboratory tests (hematology, serum chemistry, and urine) will be assessed for tolerability. The severity of the AEs and SAEs will be determined by CTCAE v5.0.
To determine the occurrence of AEs and SAEs after 4 treatment cycles by assessing the frequency, severity, causality, and nature of AEs and SAEs; also changes in ECG, vital signs (arterial blood pressure, heart rate, and temperature), and laboratory tests (hematology, serum chemistry, and urine) will be assessed for tolerability. The severity of the AEs and SAEs will be determined by CTCAE v5.0.
次要结局
- The recommended maximal dose will be defined by the safety and tolerability profile and PK data.
- Exposure levels of exidavnemab in serum (i.e., PK parameters of exidavnemab).
- Immunogenicity; determination of ADAs in serum by using a tier-based approach followed by determination of NAbs if relevant.
研究者
Tomas Odergren
Scientific
BioArctic AB
研究点 (7)
Loading locations...
相似试验
尚未招募
3 期
Study of Trastuzumab Deruxtecan with Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DO-01)Ovarian Cancer2024-516982-35-00Daiichi Sankyo Inc.182
招募中
3 期
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer (PACIFIC 8)2023-506891-28-00Astrazeneca AB280
进行中（未招募）
2 期
Taldefgrobep Alfa in Adults With Overweight and ObesityObesityNCT07281495Biohaven Therapeutics Ltd.150
尚未招募
3 期
A Phase III Study to Evaluate the Efficacy and Safety of MDR-001 in Adult Participants With Overweight or Obesity (MOBILE）NCT07274137MindRank AI Ltd738
招募中
2 期
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease2023-507303-55-00Eli Lilly & Co.224